| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 630 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 | ARTV Artiva Biotherapeutics, Inc. | Horan Christopher | Chief Tech Operations Officer | Sell | 7,002 | $9.01 | $63,072.62 | -2.3% | - | - | |
| May 19, 2026 | ARTV Artiva Biotherapeutics, Inc. | Raymon Heather | SVP, Research And Development | Sell | 3,095 | $9.01 | $27,879.14 | -2.0% | - | - | |
| May 19, 2026 | MGTX Meiragtx Holdings Plc | Forbes Alexandria69 | President &CEO | Sell | 62,000 | $9.17 | $568,540.00 | -4.3% | - | - | |
| May 19, 2026 | ARTV Artiva Biotherapeutics, Inc. | Aslan Fred | Chief Executive Officer | Sell | 27,116 | $9.01 | $244,252.79 | -1.7% | - | - | |
| May 19, 2026 | ARTV Artiva Biotherapeutics, Inc. | Bush Jennifer | COO, CLO, Compliance Officer | Sell | 8,790 | $9.01 | $79,178.56 | -2.5% | - | - | |
| May 19, 2026 | ARTV Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Chief Medical Officer | Sell | 7,037 | $9.01 | $63,386.48 | -4.6% | - | - | |
| May 19, 2026 | RLYB Rallybio Corporation | Adar1 Capital Management, LLC73 | 10% Owner | Buy | 16,209 | $13.98 | $226,563.18 | +0.6% | - | - | |
| May 18, 2026 | ZBIO Zenas Biopharma, Inc. | Moulder Leon O Jr79 | Chief Executive Officer | Buy | 60,000 | $16.88 | $1,012,800.00 | +162.5% | - | - | |
| May 18, 2026 | BCDA Biocardia, Inc. | Altman Peter46 | President And CEO | Buy | 5,700 | $0.92 | $5,244.00 | +2.0% | - | - | |
| May 18, 2026 | CNSP Cns Pharmaceuticals, Inc. | Charles Faith L.50 | Director | Buy | 7,100 | $4.79 | $34,001.90 | New | - | - | |
| May 18, 2026 | IRD Opus Genetics, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund | Director, See Remarks | Sell | 1,700,000 | $4.35 | $7,395,000.00 | -31.0% | - | - | |
| May 18, 2026 | ADPT Adaptive Biotechnologies Corporation | Piskel Kyle | Chief Financial Officer | Sell | 3,115 | $13.04 | $40,619.60 | -1.2% | - | - | |
| May 18, 2026 | MPLT Maplight Therapeutics, Inc. | Kroeger Christopher A. | Chief Executive Officer | Sell | 118,235 | $27.19 | $3,214,999.73 | -4.1% | - | - | |
| May 15, 2026 | ACIU Ac Immune SA | Pfeifer Andrea | Chief Executive Officer | Sell | 10,000 | $2.79 | $27,935.00 | -0.3% | - | - | |
| May 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | Lin Patrick | Chief Business - Strategy Off | Buy | 1,369 | $2.97 | $4,065.93 | +22.0% | - | - | |
| May 15, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Ramasastry Saira54 | Director | Sell | 2,000 | $109.47 | $218,940.00 | -100% | - | - | |
| May 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | Ng George K | Chief Executive Officer | Buy | 1,843 | $2.97 | $5,473.71 | +30.7% | - | - | |
| May 15, 2026 | PCSA Processa Pharmaceuticals, Inc. | Young David | Pres. Research &Development | Buy | 1,545 | $2.97 | $4,588.65 | +11.2% | - | - | |
| May 15, 2026 | BCAX Bicara Therapeutics Inc. | Cohlhepp Ryan52 | President And COO | Sell | 12,500 | $20.29 | $253,648.75 | -3.1% | - | - | |
| May 15, 2026 | RLYB Rallybio Corporation | Adar1 Capital Management, LLC73 | 10% Owner | Buy | 79,559 | $13.99 | $1,112,976.94 | +2.3% | - | - | |
| May 14, 2026 | ABCL Abcellera Biologics Inc. | Montalbano John S.52 | Director | Buy | 20,000 | $4.77 | $95,400.00 | +9.0% | - | - | |
| May 14, 2026 | CYTK Cytokinetics, Incorporated | Blum Robert I51 | President &CEO | Sell | 7,500 | $77.92 | $584,400.00 | -1.8% | - | - | |
| May 13, 2026 | CVM Cel-Sci Corporation | Kersten Geert R | Chief Executive Officer | Buy | 100,000 | $1.19 | $119,000.00 | +81.6% | - | - | |
| May 13, 2026 | HALO Halozyme Therapeutics, Inc. | Torley Helen60 | President And CEO | Sell | 50,000 | $68.68 | $3,433,874.74 | -0.5% | - | - | |
| May 13, 2026 | ANL Adlai Nortye Ltd. | Lu Yang | CEO | Sell | 10 | $13.18 | $131.80 | - | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.